- Home
- PRAX vs DNTH Comparison
PRAX vs DNTH Comparison
Compare PRAX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- DNTH
- Stock Information
- Founded
- PRAX 2015
- DNTH 2015
- Country
- PRAX United States
- DNTH United States
- Employees
- PRAX N/A
- DNTH N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- PRAX Health Care
- DNTH Health Care
- Exchange
- PRAX Nasdaq
- DNTH Nasdaq
- Market Cap
- PRAX 599.7M
- DNTH 568.6M
- IPO Year
- PRAX 2020
- DNTH N/A
- Fundamental
- Price
- PRAX $46.32
- DNTH $18.38
- Analyst Decision
- PRAX Strong Buy
- DNTH Strong Buy
- Analyst Count
- PRAX 11
- DNTH 7
- Target Price
- PRAX $114.73
- DNTH $53.00
- AVG Volume (30 Days)
- PRAX 299.7K
- DNTH 301.8K
- Earning Date
- PRAX 08-12-2025
- DNTH 08-07-2025
- Dividend Yield
- PRAX N/A
- DNTH N/A
- EPS Growth
- PRAX N/A
- DNTH N/A
- EPS
- PRAX N/A
- DNTH N/A
- Revenue
- PRAX $8,122,000.00
- DNTH $6,524,000.00
- Revenue This Year
- PRAX N/A
- DNTH N/A
- Revenue Next Year
- PRAX $6,358.50
- DNTH N/A
- P/E Ratio
- PRAX N/A
- DNTH N/A
- Revenue Growth
- PRAX 270.02
- DNTH 102.36
- 52 Week Low
- PRAX $26.70
- DNTH $13.37
- 52 Week High
- PRAX $91.83
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- PRAX 63.87
- DNTH 50.94
- Support Level
- PRAX $40.93
- DNTH $17.27
- Resistance Level
- PRAX $44.40
- DNTH $18.78
- Average True Range (ATR)
- PRAX 2.26
- DNTH 1.14
- MACD
- PRAX -0.08
- DNTH 0.11
- Stochastic Oscillator
- PRAX 95.12
- DNTH 59.18
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.